Clinical trial
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487 is registered in ClinicalTrials.gov with TScan Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Lead sponsor
- TScan Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- May 6, 2024
- Completion date
- December 30, 2026
- Enrollment
- 840 (estimated)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.
anogenital cancers, cervical cancer, head and neck cancer, hpv - anogenital human papilloma virus infection, hpv positive oropharyngeal squamous cell carcinoma, hpv positive rectal squamous cell carcinoma, hpv-associated vaginal adenocarcinoma, hpv-related adenocarcinoma, hpv-related adenosquamous carcinoma, hpv-related anal squamous cell carcinoma, hpv-related carcinoma, hpv-related cervical carcinoma, hpv-related endocervical adenocarcinoma, hpv-related malignancy, hpv-related penile squamous cell carcinoma, hpv-related squamous cell carcinoma, hpv-related verrucous carcinoma, hpv-related vulvar squamous cell carcinoma, melanoma, non-small cell carcinoma, ovarian cancer